IGHV status was also predictive of TFT, with median TFT for M-CLL patients 36.4 years as compared to 2.76 years for U-CLL patients (HR 6.28, 95%CI 2.61–15.1, P < 0.0001), and both FCRL2 and IGHV status were superior predictors relative to CD38 (data not shown). This evidence concerns the gene FCRL2 and B-cell chronic lymphocytic leukemia.